After selling its lead product to Allergan last year for $587.5 million, TARIS Biomedical has pivoted into developing a bladder cancer drug device combination with a $32 million investment.
Vertex Pharmaceuticals founder Joshua Boger says that venture capitalists have too much of a say in how to shape a startup - when really, it should be left up to a solid team of scientists.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.